WO2023128990A1 - Inhibitory effects of standardized extracts of salvia triloba leaves on cox-1, cox-2 and lox enzymes - Google Patents

Inhibitory effects of standardized extracts of salvia triloba leaves on cox-1, cox-2 and lox enzymes Download PDF

Info

Publication number
WO2023128990A1
WO2023128990A1 PCT/TR2022/051140 TR2022051140W WO2023128990A1 WO 2023128990 A1 WO2023128990 A1 WO 2023128990A1 TR 2022051140 W TR2022051140 W TR 2022051140W WO 2023128990 A1 WO2023128990 A1 WO 2023128990A1
Authority
WO
WIPO (PCT)
Prior art keywords
cox
leaves
salvigenin
salvia triloba
extract
Prior art date
Application number
PCT/TR2022/051140
Other languages
French (fr)
Inventor
Ayşe Esra KARADAĞ
Fatma TOSUN
Sevde Nur BILTEKIN KALELI
Original Assignee
Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2021/021393 external-priority patent/TR2021021393A2/en
Application filed by Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi filed Critical Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi
Publication of WO2023128990A1 publication Critical patent/WO2023128990A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Definitions

  • the present invention relates to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent.
  • the inventors aim to develop anti-inflammatory agents derived from herbal or natural sources, which can be standardized in terms of the amount of pharmaceutically active substances contained therein.
  • the present invention is directed to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent or to compounds comprising salvigenin in any proportion, for example, 1% - 99%, preferably plant extracts comprising 1% - 99% salvigenin, in particular preferably Salvia triloba leaves extracts comprising 1%> - 95% salvigenin, for example, Salvia triloba leaves extracts comprising 1% - 5% salvigenin.
  • a natural anti-inflammatory agent is provided to patients with a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent according to the invention.
  • the present invention is directed to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent.
  • Another embodiment of the invention is directed to a standardized extract of Salvia triloba leaves comprising at least 1%, preferably 1-5% salvigenin for use as an anti-inflammatory agent.
  • the amount of % salvigenin mentioned in the scope of the invention is determined by any method of analysis used in the determination of salvigenin in the extract of Salvia triloba leaves, for example, HPLC and/or HPTLC device analysis, according to the Turkish Pharmacopoeia-II monographs (European pharmacopeia adaptation) - 2016 (Ministry of Health of Republic of Turkey, Turkish Medicines and Medical Devices Agency, I. Edition, 2016).
  • anti-inflammatory agent used here includes agents that show the effect as COX-1 and/or COX-2 and/or LOX inhibitors.
  • the ratio % mentioned in the context of the present invention is a relative ratio and refers to the amount of salvigenin compared to the total amount of substance in the Salvia triloba leaves extract sample subjected to analysis. For example, if the area of the entire peak obtained in the HPLC analysis of the Salvia triloba leaves extract sample is expressed as 100, the area of the peak corresponding to salvigenin in Salvia triloba leaves extract sample according to the invention should be at least 1.
  • the invention relates to pharmaceutical compositions comprising a standardized extract of Salvia triloba leaves suitable for use as an anti-inflammatory agent comprising at least 1%, preferably in the range of 1-5% salvigenin.
  • Another aspect of the invention is the use of another anti-inflammatory agent in addition to the said active ingredient in pharmaceutical compositions comprising a standardized extract of Salvia triloba leaves comprising at least 1%, preferably 1-5%, salvigenin as the active ingredient.
  • said additional anti-inflammatory agents may be ibuprofen or diclofenac.
  • Combinations according to the invention may be formulated in the same dosage form or different dosage forms.
  • the combination formulations according to the invention are formulated in different dosage forms, the said formulations may be used at different times or simultaneously or sequentially.
  • Formulations according to the invention may be formulated in a dosage form suitable for oral or topical use.
  • Oral formulations may be in any of the forms of tablet, capsule, extended- release capsule, delayed-release capsule, syrup, emulsion, suspension, coated tablet, layered tablet, orally disintegrating tablet, effervescent tablet, sachet, sublingual tablet.
  • Topical formulations may be in any of the forms of ointment, cream, gel, hydrogel, or lotion.
  • Formulations according to the invention may comprise at least one pharmaceutically acceptable excipient in addition to the extract of Salvia triloba leaves comprising at least 1% salvigenin. Said excipient may not have any therapeutic effect but may be used to fulfill a requirement arising during the preparation or preservation or use of the formulation.
  • agents of natural origin suitable for use as anti-inflammatory agents have been developed.
  • the invention is of interest to both end-users in the healthcare sector and drug developers.
  • Example 1 IC50 values for COX-1 and COX-2 inhibition of Salvia triloba leaves extract according to the invention and comparison thereof with known anti-inflammatory agents
  • Salvia triloba leaves extract used in the study whose results are given below comprises 3.7% salvigenin.
  • Example 1 When the results in Example 1 are evaluated, it is seen that the standardized extract of Salvia triloba leaves according to the invention over salvigenin shows better or significantly close anti-inflammatory effect than anti-inflammatory agents used commercially for a long time, although it is a natural extract.
  • the anti-inflammatory effect mentioned here is shown through COX-1 and/or COX-2 inhibition.
  • the standardized extract of Salvia triloba leaves according to the invention over salvigenin is more effective on COX-2 than both known agents, and that this extract according to the invention does not have the stomach irritant effect often seen in some anti-inflammatory agents.
  • the standardized extracts according to the invention are superior to the agents available in the known art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent.

Description

INHIBITORY EFFECTS OF STANDARDIZED EXTRACTS OF SALVIA TRILOBA LEAVES ON COX-1, COX-2 AND LOX ENZYMES
Technical Field
The present invention relates to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent.
State of the Art
Diseases caused by inflammation are frequently encountered. Inflammations that occur in different parts of the body for different reasons are tried to be treated with various conventional drugs. However, treatment with these agents is sometimes inadequate and the discovery of novel and natural anti-inflammatory agents is of great importance.
One of the most common problems in the commercial use of therapeutic agents of natural origin is that the amount of pharmaceutically active substances in the extracts obtained from natural products is not constant. The variation in this amount, which may vary depending on the region or period of collection of the plant, prevents the development of reproducible and standardizable formulations using plant-based extracts.
Considering the state of the art, it is obvious that there is a need for pharmaceutical quality anti-inflammatory agents that can be both obtained from herbal or natural sources and standardized in terms of the amount of substances that show pharmaceutical activity.
Aim of the Invention
The inventors aim to develop anti-inflammatory agents derived from herbal or natural sources, which can be standardized in terms of the amount of pharmaceutically active substances contained therein.
Brief Description of the Invention
The present invention is directed to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent or to compounds comprising salvigenin in any proportion, for example, 1% - 99%, preferably plant extracts comprising 1% - 99% salvigenin, in particular preferably Salvia triloba leaves extracts comprising 1%> - 95% salvigenin, for example, Salvia triloba leaves extracts comprising 1% - 5% salvigenin.
Since the standardized extracts in terms of salvigenin are used in the invention, the results of the study are reproducible and debatable.
Furthermore, since there are not many agents that selectively inhibit COX and LOX enzymes, a natural anti-inflammatory agent is provided to patients with a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent according to the invention.
Detailed Description of the Invention
The present invention is directed to a standardized extract of Salvia triloba leaves over salvigenin for use as an anti-inflammatory agent.
Another embodiment of the invention is directed to a standardized extract of Salvia triloba leaves comprising at least 1%, preferably 1-5% salvigenin for use as an anti-inflammatory agent.
The amount of % salvigenin mentioned in the scope of the invention is determined by any method of analysis used in the determination of salvigenin in the extract of Salvia triloba leaves, for example, HPLC and/or HPTLC device analysis, according to the Turkish Pharmacopoeia-II monographs (European pharmacopeia adaptation) - 2016 (Ministry of Health of Republic of Turkey, Turkish Medicines and Medical Devices Agency, I. Edition, 2016).
The term anti-inflammatory agent used here includes agents that show the effect as COX-1 and/or COX-2 and/or LOX inhibitors.
The ratio % mentioned in the context of the present invention is a relative ratio and refers to the amount of salvigenin compared to the total amount of substance in the Salvia triloba leaves extract sample subjected to analysis. For example, if the area of the entire peak obtained in the HPLC analysis of the Salvia triloba leaves extract sample is expressed as 100, the area of the peak corresponding to salvigenin in Salvia triloba leaves extract sample according to the invention should be at least 1. In a further aspect, the invention relates to pharmaceutical compositions comprising a standardized extract of Salvia triloba leaves suitable for use as an anti-inflammatory agent comprising at least 1%, preferably in the range of 1-5% salvigenin.
Another aspect of the invention is the use of another anti-inflammatory agent in addition to the said active ingredient in pharmaceutical compositions comprising a standardized extract of Salvia triloba leaves comprising at least 1%, preferably 1-5%, salvigenin as the active ingredient.
In one embodiment of the invention, said additional anti-inflammatory agents may be ibuprofen or diclofenac.
Combinations according to the invention may be formulated in the same dosage form or different dosage forms.
If the combination formulations according to the invention are formulated in different dosage forms, the said formulations may be used at different times or simultaneously or sequentially.
Formulations according to the invention may be formulated in a dosage form suitable for oral or topical use. Oral formulations may be in any of the forms of tablet, capsule, extended- release capsule, delayed-release capsule, syrup, emulsion, suspension, coated tablet, layered tablet, orally disintegrating tablet, effervescent tablet, sachet, sublingual tablet. Topical formulations may be in any of the forms of ointment, cream, gel, hydrogel, or lotion.
Formulations according to the invention may comprise at least one pharmaceutically acceptable excipient in addition to the extract of Salvia triloba leaves comprising at least 1% salvigenin. Said excipient may not have any therapeutic effect but may be used to fulfill a requirement arising during the preparation or preservation or use of the formulation.
Industrial Applicability
Thanks to the invention, agents of natural origin suitable for use as anti-inflammatory agents have been developed.
In this respect, the invention is of interest to both end-users in the healthcare sector and drug developers.
Examples Example 1 : IC50 values for COX-1 and COX-2 inhibition of Salvia triloba leaves extract according to the invention and comparison thereof with known anti-inflammatory agents
Salvia triloba leaves extract used in the study whose results are given below comprises 3.7% salvigenin.
Figure imgf000005_0001
When the results in Example 1 are evaluated, it is seen that the standardized extract of Salvia triloba leaves according to the invention over salvigenin shows better or significantly close anti-inflammatory effect than anti-inflammatory agents used commercially for a long time, although it is a natural extract. The anti-inflammatory effect mentioned here is shown through COX-1 and/or COX-2 inhibition. The better COX-1 and COX-2 inhibition compared to ibuprofen and diclofenac, which have been frequently used anti-inflammatory agents in the pharmaceutical market for many years, suggests that these natural standardized extracts may be important anti-inflammatory agents. Furthermore, it can be seen from the table above that the standardized extract of Salvia triloba leaves according to the invention over salvigenin is more effective on COX-2 than both known agents, and that this extract according to the invention does not have the stomach irritant effect often seen in some anti-inflammatory agents. In this respect, the standardized extracts according to the invention are superior to the agents available in the known art.

Claims

1. Standardized extract of Salvia triloba leaves comprising at least 1% salvigenin for use as an anti-inflammatory agent.
2. The standardized extract of Salvia triloba leaves comprising at least 1% salvigenin for use as an inhibitor of COX- 1 and/or COX-2 and/or LOX enzyme according to claim 1.
3. An extract according to claim 1 or 2, comprising salvigenin in the range of 1-5%.
4. Pharmaceutical compositions comprising a standardized extract of Salvia triloba leaves comprising at least 1% salvigenin as the active ingredient, suitable for use as an antiinflammatory agent.
5. A pharmaceutical composition according to claim 4, further comprising another antiinflammatory agent.
6. A pharmaceutical composition according to claim 5, wherein the additional antiinflammatory agent is diclofenac or ibuprofen.
7. A pharmaceutical composition according to any one of claims 4-6, formulated in a dosage form suitable for oral or topical use.
5
PCT/TR2022/051140 2021-12-28 2022-10-17 Inhibitory effects of standardized extracts of salvia triloba leaves on cox-1, cox-2 and lox enzymes WO2023128990A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021/021393 TR2021021393A2 (en) 2021-12-28 INHIBITORY EFFECTS OF STANDARDIZED EXTRACTS OF SALVIA TRILOBA LEAVES ON COX-1, COX-2 AND LOX ENZYMES
TR2021021393 2021-12-28

Publications (1)

Publication Number Publication Date
WO2023128990A1 true WO2023128990A1 (en) 2023-07-06

Family

ID=86999875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/051140 WO2023128990A1 (en) 2021-12-28 2022-10-17 Inhibitory effects of standardized extracts of salvia triloba leaves on cox-1, cox-2 and lox enzymes

Country Status (1)

Country Link
WO (1) WO2023128990A1 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOUFADI MOKHTARIA YASMINA, KEDDARI SOUMIA, MOULAIHACENE FAIZA, CHAA SARA: "Chemical Composition, Antioxidant and Anti-Inflammatory Properties of Salvia Officinalis Extract from Algeria", PHARMACOGNOSY JOURNAL, vol. 13, no. 2, 4 March 2020 (2020-03-04), pages 506 - 515, XP093078316, DOI: 10.5530/pj.2021.13.64 *
MANSOURABADI AMIR HOSSEIN, SADEGHI HAMID MOHAMMAD, RAZAVI NASTARAN, REZVANI EBRAHIM: "Anti-inflammatory and Analgesic Properties of Salvigenin, Salvia officinalis Flavonoid Extracted", ADVANCED HERBAL MEDICINE, vol. 2, no. 1, 1 January 2016 (2016-01-01), pages 31 - 41, XP093078187 *

Similar Documents

Publication Publication Date Title
AU2003286549C1 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7431948B2 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8557306B2 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
Castro Propolis: biological and pharmacological activities. Therapeutic uses of this bee-product
EP2221052A2 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
JP5543979B2 (en) Anti-inflammatory pharmaceutical composition comprising cinnamon extract and gentian extract
Mutia et al. Hepatoprotective effect of Citrus sinensis (L.) osbeck ethanol extract in paracetamol-induced rats
Makoshi et al. Hepatoprotective effect of Phyllanthus niruri aqueous extract in acetaminophen sub-acutec exposure rabbits
JP2001513803A (en) Plant extract composition, method for producing the same, and pharmaceutical composition containing the same
US7811610B2 (en) Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
WO2023128990A1 (en) Inhibitory effects of standardized extracts of salvia triloba leaves on cox-1, cox-2 and lox enzymes
WO2023128989A1 (en) Inhibitory effects of standardized extracts of rosmarinus officinalis leaves on cox-1, cox-2 and lox enzymes
WO2023128991A1 (en) Inhibitory effects of standardized extracts of taraxacum officinale aerial parts on cox-1, cox-2 and lox enzymes
WO2023128987A1 (en) Inhibitory effects of standardized extracts of allium sativum l. onions on cox-1, cox-2 and lox enzymes
WO2023128988A1 (en) Inhibitory effects of standardized extracts of malva sylvestris flowers on cox-1, cox-2 and lox enzymes
Bharskar Review on phytochemistry and pharmacological aspects of Pedalium murex Linn
WO2023128999A1 (en) Natural compounds with anti-inflammatory effect
WO2023128984A1 (en) Cox-1, cox-2 and lox enzyme inhibiting effects of standardized extracts of crataegus monoygna fruits and leaves with flowerleaves with flowers
TR2021021389A1 (en) INHIBITORY EFFECTS OF ROSMARINIC ACID ON COX-1, COX-2 AND LOX ENZYMES
TR2021021396A1 (en) INHIBITORY EFFECTS OF CHLOROGENIC ACID ON COX-1, COX-2 AND LOX ENZYMES
TR2021021403A1 (en) INHIBITORY EFFECTS OF VITEXIN-2-O-RAMNOSITE ON COX-1, COX-2 AND LOX ENZYMES
TR2021021379A1 (en) INHIBITORY EFFECTS OF MALVIN ON COX-1, COX-2 AND LOX ENZYMES
TR2021021394A1 (en) INHIBITORY EFFECTS OF SALVIGENIN ON COX-1, COX-2 AND LOX ENZYMES
Rojas-Bedolla et al. Chemical characterization, pharmacological effects, and toxicity of an ethanol extract of Celtis pallida Torr.(Cannabaceae) aerial parts
Sathiyabalan et al. Anti-inflammatory activity of whole plant of Petiveria alliacea L.(Phytolaccaceae)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22916993

Country of ref document: EP

Kind code of ref document: A1